following a full submission:
upadacitinib (Rinvoq®) is accepted for use within NHSScotland.
Indication under review: for the treatment of active ankylosing spondylitis (AS) in adult patients who have responded inadequately to conventional therapy.
In a phase III and a phase II/III study, upadacitinib when compared with placebo, significantly improved symptoms of AS in adults with active disease that was inadequately controlled with non-steroidal anti-inflammatory drugs (NSAIDs).
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Download detailed advice828KB (PDF)
Medicine details
- Medicine name:
- upadacitinib (Rinvoq)
- SMC ID:
- SMC2480
- Indication:
Treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.
- Pharmaceutical company
- AbbVie Ltd
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 07 November 2022